Retifanlimab (MGA-012) is a blocking antibody that targets programmed cell death protein 1 (PD-1). By binding to the PD-1 receptor on the surface of T cells, retifanlimab blocks its interaction with the ligands PD-L1 and PD-L2, thereby reversing the immune suppression mediated by the PD-1 pathway and exerting an antitumor effect. Retifanlimab is indicated for the treatment of Merkel cell carcinoma.

PD-1 (human):3.71 ng/mL (EC50)

瑞弗利单抗, MGA-012, MGA012, INCMGA-0012, INCMGA0012, AEX-1188, AEX1188

Human

Monoclonal

Unconjugated